作者: Connolly, Heidi M ; Egbe, Alexander C. ; Connolly, Heidi M. ; Hsu, Andrea ; Egbe, Alexander C ; Miranda, William R ; Dearani, Joseph A. ; Ali, Ahmed E. ; Ali, Ahmed E ; Dearani, Joseph A ; Miranda, William R.

BACKGROUNDMiddle-aged Fontan patients are underrepresented in contemporary studies. The purpose of this study was to describe the clinical characteristics and outcomes in middle-aged patients with Fontan palliation.METHODSAll adults with Fontan palliation were divided into 'middle-aged' group (>40 years of age at baseline encounter), and 'young adult' group. Clinical characteristics were assessed across multiple domains (atrial arrhythmias, heart failure, and hepatorenal function). Clinical outcomes were assessed as composite outcome of death/heart transplant.RESULTSOf 455 adults (median age 26 years), 63 (14 %) were middle-aged adults while 392 (86 %) were young adults. Compared to the young adult group, the middle-aged group had a higher prevalence of atrial arrhythmias, greater neurohormonal activation, and worse hepatorenal function. Of 63 patients in the middle-aged group, 26 (41 %) patients died, and 4 (6 %) patients underwent heart transplant. The middle-aged group had a higher 5-year cumulative incidence of death/transplant (45 % versus 21 %, p < 0.001), and 10-year cumulative incidence of death/transplant (64 % versus 29 %, p < 0.001) compared to the young adult group. Higher pulmonary artery wedge pressure (hazard ratio 1.18 [1.09-1.27]), and higher model for end-stage liver disease excluding international normalized ratio score (hazard ratio 1.07, [1.03-1.14]), were associated with death/transplant.CONCLUSIONSAbout 14 % of adults with Fontan palliation were middle-aged, and these patients had higher prevalence of cardiovascular comorbidities, hepatorenal dysfunction, and mortality. These data underscore the need for better risk stratification strategies to identify patients at risk for adverse outcomes and allow for early referral for transplant evaluation in this emerging subpopulation.CLINICAL SUMMARYThe purpose of this study was to describe the clinical characteristics (comorbidities and end-organ dysfunction) and outcomes (death/transplant) in middle-aged patients with Fontan palliation. Of 455 patients (median age 26 years), 63 (14 %) were middle-aged adults while 392 (86 %) were young adults. Compared to the young adult group, the middle-aged group had a higher prevalence of atrial arrhythmias, greater neurohormonal activation, worse hepatorenal function, and higher risk of death/transplant. The correlates of death/transplant were higher pulmonary artery wedge pressure and hepatorenal dysfunction. These data underscore the need for better risk stratification in this emerging population.

2024-12-01·American Journal of Clinical Oncology

Why Basic Science Education Matters in Radiation Oncology

Article

作者: Haffty, Bruce G. ; Zietman, Anthony L. ; Steinberg, Michael L. ; Davis, Brian J. ; Das, Prajnan ; Wallner, Paul E. ; Curran, Walter J. ; Burmeister, Jay ; Marples, Brian

2024-07-01·Journal of Shoulder and Elbow Surgery

Operative treatment of acromial and scapular spine fracture nonunions complicating reverse total shoulder arthroplasty

Article

作者: Tangtiphaiboontana, Jennifer ; Austin, Daniel C ; Esper, Ronda ; Barlow, Jonathan D ; Marigi, Erick M ; Yu, Kristin E ; Morrey, Mark E ; Sanchez-Sotelo, Joaquin

BACKGROUNDFractures of the acromion and spine can have a major impact on the outcome of reverse shoulder arthroplasty (RSA) with respect to pain, motion, and function. Reports on internal fixation for these fractures are isolated to small series or case reports with variable outcomes. The purpose of this study was to report on the outcome of open reduction and internal fixation (ORIF) of acromion or spine fractures encountered before or after RSA and describes our evolution of fixation techniques.METHODSBetween 2011 and 2023, 22 fractures or nonunions of the acromion or spine of the scapula underwent ORIF at a single institution and were followed for a minimum of 1 year. In 16 shoulders, fractures occurred after RSA, whereas 5 shoulders underwent ORIF prior to RSA. One shoulder had undergone prior failed ORIF elsewhere and revision ORIF was performed at our institution. There were 10 males and 12 females with a mean age of 67 (SD = 15.1) years. Fixation strategies included single (n = 11) and double plate fixation (n = 11). Kruskal-Wallis one-way analyses of variance were used to analyze continuous variables and Chi-square tests employed for categorical variables.RESULTSOf the 5 fractures treated with ORIF pre-RSA, 1 shoulder suffered an additional fracture medial to the hardware and 1 required additional bone grafting for incomplete union at the time of RSA. These 5 shoulders all underwent RSA uneventfully, but 1 fracture experienced late displacement of the scapular spine nonunion, leading to plate removal. Of the 16 post-RSA ORIF shoulders, radiographic union was confirmed in 14 and substantial residual inferior angulation identified in 3. New fractures occurred after ORIF in 5 shoulders. For patients who underwent ORIF after RSA, pain scores improved from a mean of 8 to 1.9 points, with more modest elevation gains (58.2°-91.3° pre and postoperatively, respectively).CONCLUSIONSORIF of acromion and scapular spine fractures or nonunions in the setting of RSA have the potential to lead to union. When these fractures and nonunions are encountered prior to RSA, ORIF allows for uneventful RSA implantation, but secondary displacement may occur. ORIF seems to lead to improvements in pain, but more modest improvements in motion and function. Our fixation strategy has evolved to (1) dual plating, (2) spanning the whole length of the spine with 1 of the plates, (3) use of hook features under the acromion or os trigonum if possible, and (4) liberal use of bone graft.

项与 Mayo Medical School 相关的新闻（医药）

2024-01-28

·SYNAPSE

First Coast Cardiovascular Institute and CardioHealth Partner to Advance Cardiovascular Care for Northeast Florida Residents

First Coast Cardiovascular Institute has joined forces with CardioHealth. Together, the practices aim to advance cardiovascular care across Northeast Florida. JACKSONVILLE, Fla., Jan. 29, 2024 /PRNewswire-PRWeb/ -- First Coast Cardiovascular Institute, a Cardiovascular Logistics partner practice that offers cardiovascular medicine, sleep medicine, pulmonology, and amputation prevention to residents in Northeast Florida and Southern Georgia, has joined forces with CardioHealth, a Jacksonville-based cardiovascular practice that specializes in delivering exceptional care to patients with hypertension, congestive heart failure, atrial fibrillation, and valvular heart disease. Together, they aim to advance cardiovascular care across Northeast Florida. In this partnership, First Coast Cardiovascular Institute (FCCI) will integrate the CardioHealth team into its practice. FCCI, in conjunction with Cardiovascular Logistics, will support CardioHealth with advanced technology and data analytics to lead value-based care initiatives and back-office infrastructure and support. Three Best Rated® recently named three cardiovascular specialists from these two practices, including Yazan Khatib, MD, Sumant Lamba, MD, FACC, FSCAI, and Ramon Castello, MD, FACC, FASE, as the "best cardiologists in Jacksonville." The Three Best Rated® honor was based on a rigorous 50-point inspection, including customer reviews, history, complaints, ratings, satisfaction, trust, cost, and general excellence. "We are thrilled to partner with CardioHealth to provide the highest quality cardiovascular care to Northeast Florida patients," said Dr. Khatib, President of FCCI. "CardioHealth founder Ramon Castello is a world-renowned echocardiographer, and over the past decade, the CardioHealth team has earned an outstanding reputation for its patient care. We are confident their expertise will enhance the care we deliver for years to come." Established in 2014, CardioHealth is known for delivering quality and compassionate cardiovascular care to both English and Spanish-speaking patients in the Jacksonville metropolitan area. Dr. Castello is one of the region's few fluent Spanish-speaking cardiologists, and every CardioHealth staff member is bilingual. CardioHealth is a non-invasive practice that employs electrocardiograms, echocardiography, and other tools to diagnose and treat cardiovascular disease. "Through this partnership and integration with FCCI, CardioHealth is enhancing our non-invasive practice model to one encompassing interventional cardiology, electrophysiology, and structural heart disease, which will enable our team to deliver high-quality care to more patients," said Dr. Castello, who has served as the Director of Non-Invasive Cardiology at HCA Florida Memorial Hospital since 2008. "We also look forward to receiving technical and administrative support from First Coast Cardiovascular Institute and Cardiovascular Logistics, which will enable us to continue to focus on adding value to our patients." "This collaboration between First Coast Cardiovascular Institute and CardioHealth marks a significant milestone for both practices," said David Konur, CEO of Cardiovascular Logistics. "By joining together and leveraging their complementary strengths while receiving additional support from Cardiovascular Logistics, they are well positioned to continue delivering outstanding care to patients in Northeast Florida." About Dr. Castello Prior to CardioHealth and HCA Florida Memorial Hospital, Dr. Castello spent most of his professional career in academic medicine. He has more than 200 scientific publications. Most recently, he was a professor of medicine at the Mayo School of Medicine and the Director of the Echocardiography Laboratory at Mayo Clinic in Jacksonville. Dr. Castello served as the President of ICAEL, the national organization that grants accreditation to echocardiography laboratories nationwide. He has also served as a member of the board of directors for the American Society of Echocardiography and chair of the Fellows Committee of the American Society of Echocardiography Committee. Dr. Castello currently is a member of the National Board of Echocardiography. He graduated from the University of Valencia School of Medicine in Spain. About First Coast Cardiovascular Institute Since 2002, FCCI has built a reputation for providing compassionate care to residents of Northeast Florida and Southern Georgia. With 38 providers, the practice has consistently brought the latest advancements in medicine to the region, allowing its patients to be the first to benefit from exciting new technology. FCCI offers board-certified services in cardiovascular medicine, sleep medicine, pulmonology, amputation prevention, and stroke care and prevention. Besides clinical innovations, FCCI has pioneered healthcare delivery innovations, with successes in value-based healthcare with CMS as well as commercial payors. Learn more at www.firstcoastcardio.com. About Cardiovascular Logistics Cardiovascular Logistics (CVL) is the most comprehensive cardiovascular platform in the country. CVL is integrating the nation's best cardiology practices into one robust cardiovascular solution. CVL is fundamentally changing how cardiovascular care is delivered in the United States. The CVL platform is grounded in the mission of providing patients the highest quality of cardiovascular care available. CVL partners with Lee Equity Partners, a New York-based private equity firm. For more information, visit www.cardiovascularlogistics.com. Media Contact: Shelly Cataleta 904.347.6469 [email protected] https://firstcoastcardio.com/

高管变更AHA会议

2024-01-02

·PRNewswire

MindMD, A Groundbreaking Nutritional Supplement for Cognitive Health, Rolls Out Nationally with Endorsement from Brain Health Pioneer, Dr. Alexander Zubkov

According to the CDC, Cognitive Decline a Major Health Concern for 11% of Americans, 68.59 Million Now Between Age 59 and 77 IRVINE, Calif., Jan. 2, 2024 /PRNewswire/ -- 1MD Nutrition, makers of nutritional supplements developed by physicians, with scientifically studied ingredients and offered in clinical doses, introduces the newest SKU to its lineup of 25 condition-specific products, MindMD. Created to support cognitive health and provide neurosupportive benefits, the broad-spectrum daily product is endorsed by 30-year integrative neurology pioneer, Dr. Alexander Zubkov. MindMD will become available to the public on December 31, 2023 and retails for $79. Continue Reading MindMD Dr. Alexander Zubkov As reported by the Centers for Disease Control (CDC), cognitive decline is a major health concern affecting over 11% of adults. In 2023, Baby Boomers (born 1946-1964) are celebrating birthdays between the ages of 59 and 77 and make up the second largest American population; 68.59 million people. A key player in the MindMD formula is Bacognize, a proprietary extract of Bacopa monnieri. This adaptogenic powerhouse is standardized to support cognitive function and acuity, fostering focus and learning. Another star ingredient in MindMD is Cognigrape, a standardized red grape juice powder extract packed with bioactive flavonoids, anthocyanin, and proanthocyanidin. Cognigrape was added to address the multifaceted aspects of cognitive health, supporting both immediate and delayed memory function and attention. To enhance neuro-support, MindMD incorporates phosphatidylserine and vitamin B6. These nutrients work together to support concentration, accuracy, learning, and memory. Additionally, the combination of folate and green tea leaf extract plays an important role in reducing typical oxidative stress in the brain. The MindMD formula is in the midst of a randomized controlled study. The study group entered into the trial with a 6-month intervention period and researchers are benchmarking cognitive changes by using a questionnaire-styled battery of cognitive tests at Day 0, 90 and 180. Details of the trial will be published with results in 2024. One of the nation's foremost authorities on the use of an integrative approach for long-term cognitive health, Dr. Alexander Zubkov, has joined the stable of 1MD Nutrition physicians who, each in their own area of expertise, are shaping the future of medicine; they include: interventional cardiologist, Dr. Heather Shenkman, dual board-certified rheumatologist and internal medicine specialist, Dr. Adam Kreitenberg, Gastroenterologist, Dr. David Kahana, Immunologist and Allergist, Dr. Brian Greenberg and Urologist, Dr. Daniel Brison. "I am a neurologist dedicated to advancing brain health who started in Western medicine managing strokes and neurocritical care, but I am not content with crisis care," said Dr. Alexander Zubkov, "I extended my practice to include integrative, functional medicine when I noticed a surge in younger patients grappling with chronic brain issues. A paradigm shift needs to happen in healthcare that emphasizes prevention and addresses the root causes of chronic diseases. I proudly stand behind 1MD Nutrition's MindMD. This product stands head and shoulders above other cognitive support supplements on the market with its innovative blend of carefully selected ingredients - each backed by science." Dr. Zubkov served as a neuroscience fellow at the Mayo Clinic, Chief Resident at the University of Mississippi Medical Center, Assistant Professor of Neurology and faculty at the Mayo School of Graduate Medical Education and the University of Minnesota. Zubkov's influence in the world of brain neurology extends beyond academia where he also served as the Medical Director of the Fairview Southdale Hospital Stroke Program in Minneapolis, Minnesota. About - Healthcare & Pharmaceutical Awards 2023 Best Dietary Supplements winner, 1MD Nutrition, partners with renowned physicians to develop health supplements formulated with clean, scientifically researched ingredients at their clinically effective dosages. All product facilities abide by GMP standards and are NSF and/or SQF-Certified. 1MD Nutrition is known for its superlative choices of ingredients that have been rigorously proven in clinical trials and meet Good Manufacturing Practices. Media Contact: Alyson Dutch 3104567151 [email protected] SOURCE 1MD Nutrition

2023-12-19

·Business Wire

IEEE EMBS Executive Committee Appoints Dr. Erika Ross Ellison as President-Elect, Along With Two New Vice Presidents

PISCATAWAY, N.J.--( BUSINESS WIRE )--IEEE, the world’s largest technical professional organization dedicated to advancing technology for humanity, and the IEEE Engineering in Medicine and Biology Society (EMBS) , today announced the results of its executive committee elections, in which Dr. Erika Ross Ellison was appointed president-elect of the society for the 2025 term. In addition, Drs. Beena Ahmed and Natalie Mrachacz-Kersting were elected vice president of Conferences and vice president of Member and Student Activities, respectively. Their two-year terms will also commence in 2025, at which time, Paul Sajda, Ph.D., current president of IEEE EMBS, will serve as past president, and Metin Akay, current past president, will serve as an ambassador. “I want to offer my warmest congratulations to all three of our new leader-elects,” said Dr. Sajda. “Their remarkable achievements throughout the course of their careers promise to usher in an era of growth and innovation at IEEE EMBS.” Dr. Erika Ross Ellison Dr. Ross Ellison currently serves as the vice president of Global Clinical, Regulatory, and Quality at ONWARD Medical, a medical technology company that generates movement-restoring therapies for individuals with spinal cord injuries. Previously, she served as director of Clinical and Applied Research at Abbott Neuromodulation, where she led the global research team, oversaw strategy, and conducted research studies for the company’s spinal cord and deep brain stimulation systems. Dr. Ross Ellison’s other professional experiences include: neuroscience director at Cala Health; deputy director, Medical Device Innovation Accelerator at Mayo Clinic; and assistant professor of Neurologic Surgery, also at Mayo Clinic. “My top objective will be to establish IEEE EMBS as the largest global forum for biomedical engineers, clinicians and scientists,” said Dr. Ross Ellison. “As president, I will prioritize three key aspects: nurturing collaboration between academia and industry; promoting the development and mentorship of students; and championing diversity and inclusion. I know that, together, we can raise awareness of IEEE EMBS’s commitment to advancing the research and development work of biomedical engineers.” Dr. Ross Ellison earned her B.S. in biology and business, and an M.S. in molecular biology from the University of Denver. She earned her Ph.D. in neuroscience from the Mayo Clinic Graduate School of Biomedical Sciences, in which her research focused on the development of novel deep brain stimulation methods for Parkinson’s and Alzheimer’s disease. Dr. Beena Ahmed Since 2017, Dr. Ahmed has been an associate professor in Signal Processing with the School of Electrical Engineering and Telecommunications at the University of New South Wales, Sydney, Australia (UNSW). Previously, she was an assistant professor at Texas A&M University in Qatar. She is the technical representative on the IEEE EMBS administrative committee, and served as program co-chair of EMBC 2023. Dr. Ahmed earned her Ph.D. in signal processing from UNSW, and received her B.Sc in electrical engineering from the University of Engineering and Technology, Lahore, Pakistan. Her current research interests are on applying machine learning and remote monitoring in healthcare and therapeutic applications. She has received many prestigious awards, including the 2020 Innovation Award from Speech Pathology Australia; the 2021 Women in AI; the 2022 Telstra Digital Health Award; and the 2023 American Speech and Hearing Association’s Gamechanger Award. She is the co-founder and chief technology officer of Say66, which works to create new speech therapies. Dr. Natalie Mrachacz-Kersting Dr. Mrachacz-Kersting is currently a neuroscience professor at the Albert-Ludwigs University of Freiburg. She has held previous faculty positions at Aalborg University, Denmark; FH Dortmund, Germany; and the University of Auckland, New Zealand. She is an IEEE EMBS practitioner representative, and is active on the IEEE Brain steering committee. Dr. Mrachacz-Kersting received her Ph.D. in biomedical science and engineering from the University of Aalborg. Her current research focuses on the development of neurorehabilitation technology for the restoration of lost motor function. She has authored more than 80 articles in peer-reviewed journals, approximately 150 conference articles/abstracts, and ten book chapters. Moreover, she has earned the International Award in Brain Computer Interfaces, in addition to numerous prestigious grants. About the IEEE Engineering in Medicine and Biology Society The IEEE Engineering in Medicine and Biology Society (EMBS) is the world's largest international society of biomedical engineers. With more than 9,500 members residing in some 97 countries around the world, IEEE EMBS is a true global connection, fostering fellowship and providing access to the most fascinating people, best practices, new information, innovative ideas and a variety of expert opinions from one of science's fastest growing fields: biomedical engineering. From formalized mathematical theory through experimental science, and from technological development to practical clinical applications, IEEE EMBS members support scientific, technological and educational activities as they apply to the concepts and methods of the physical and engineering sciences in biology and medicine. By working together, we can transform and revolutionize the future of medicine and healthcare. For more information about the IEEE EMBS, please visit www.embs.org .

高管变更

100 项与 Mayo Medical School 相关的药物交易

登录后查看更多信息

100 项与 Mayo Medical School 相关的转化医学

登录后查看更多信息